Insider · CIK 0001799732

Freeman Roy Lester

Reports to the SEC for 1 company · ATLANTA, GA

sec.gov

Transactions

Companies

Filings

CIK

0001799732

Forms 4 and 5

Insider transactions

21 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-02-14	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+22.6K sh	—	—	22,640
2025-01-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−21.9K sh	—	—	0
2025-01-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+21.9K sh	—	—	21,854
2025-01-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−1,138 sh	—	—	0
2025-01-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+1,138 sh	—	—	1,138
2025-01-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−3,780 sh	—	—	0
2025-01-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+3,780 sh	—	—	3,780
2025-01-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−6,667 sh	—	—	0
2025-01-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+6,667 sh	—	—	6,667
2025-01-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−6,667 sh	—	—	0
2025-01-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+6,667 sh	—	—	6,667
2025-01-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−30K sh	—	—	0
2025-01-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2025-01-03	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+344K sh	—	—	344,452
2025-01-03	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+172K sh	—	—	172,191
2025-01-03	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+317K sh	—	—	316,647
2024-07-16	IKTInhibikase Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2023-06-30	IKTInhibikase Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+6,667 sh	—	—	6,667
2022-06-24	IKTInhibikase Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+40K sh	—	—	40,000
2021-06-25	IKTInhibikase Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+22.7K sh	—	—	22,677
2020-12-22	IKTInhibikase Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+6,825 sh	—	—	6,825

Recent filings

Accepted (ET)
Feb 194
Freeman Roy Lester0000950170-25-023592
SEC(opens sec.gov)
Jan 224
Freeman Roy Lester0000950170-25-007742
SEC(opens sec.gov)
Jan 74
Freeman Roy Lester0000950170-25-003125
SEC(opens sec.gov)
Jul 184
Freeman Roy Lester0000950170-24-084655
SEC(opens sec.gov)
Jul 54
Freeman Roy Lester0000950170-23-031850
SEC(opens sec.gov)
Jun 284
Freeman Roy Lester0001209191-22-039712
SEC(opens sec.gov)
Jun 294
Freeman Roy Lester0001104659-21-086988
SEC(opens sec.gov)

Companies

Inhibikase Therapeutics, Inc.DirectorIKT

Address

3350 RIVERWOOD PARKWAY SE, SUITE 1900

ATLANTA, GA, 30339